Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia

Experimental Hematology & Oncology

Richard L Momparler¹ 

[1] Département de pharmacologie, Université de Montréal and Service d’hématologie/oncologie, CHU-Saint-Justine, 3175 Cote Sainte-Catherine, Montréal QC H3T 1C5, Canada

关键词: Drug resistance;    Pharmacology;    Acute myeloid leukemia;    Cytosine arabinoside;    Cytarabine;   

Others  :  812115
DOI  :  10.1186/2162-3619-2-20

 received in 2013-07-20, accepted in 2013-07-31,  发布年份 2013

【 摘 要 】

Cytarabine (cytosine arabinoside) is one of the most effective drugs for the treatment of acute myeloid leukemia. The standard dose of cytarabine used to treat this leukemia is 100 mg per square meter. In an attempt to improve the effectiveness of cytarabine against acute myeloid leukemia, a high-dose treatment (3,000 mg per square meter) was introduced into therapy. The side effects of high-dose cytarabine was a major concern, especially its neurological toxicity. A review of recent clinical trials indicates that this high-dose cytarabine can be replaced by the intermediate-dose of 1,000 mg per square meter without loss of efficacy and with less toxicity. This is an important step to improve the efficacy of cytarabine for the treatment of acute myeloid leukemia. Despite the improvements in the therapy for this leukemia, the current overall survival rate for adult patients is less than 30%. To optimize the cytarabine therapy, it is important to determine how some leukemic stem cells survive treatment. Preclinical data suggest that survival of the leukemic stem cells could be due to the long 12 hour interval between infusions of cytarabine, which permits some leukemic cells to escape its S phase specific action. Among the other factors that can lead to leukemic cell survival are the high levels in the liver and spleen of cytidine deaminase, the enzyme that inactivates cytarabine and drug resistance due to deficiency in deoxycytidine kinase, the enzyme that activates the prodrug, cytarabine. Several approaches are proposed in this commentary to overcome these impediments with the goal of increasing the effectiveness of cytarabine for the treatment of acute myeloid leukemia.

【 授权许可】

   
2013 Momparler; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Löwenberg B, Downing JR, Burnet A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
• [2]Momparler RL: A model for the chemotherapy of acute leukemia with 1-ß- arabinofuranosylcytosine. Cancer Res 1974, 34:1775-1787.
• [3]Reese ND, Schiller GJ: High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep 2013, 8:141-148.
• [4]Rudnick SA, Cadman EC, Capizzi RL, et al.: High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979, 44:1189-1193.
• [5]Early AP, Preisler HD, Slocum H, et al.: A pilot study of high-dose 1-beta-D- arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res 1982, 42:1587-1594.
• [6]Herzig RH, Wolff SN, Lazarus HM, et al.: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983, 62:361-369.
• [7]Herzig RH, Hines JD, Herzig GP, et al.: Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987, 5:927-932.
• [8]Lauzon GJ, Paterson AR, Belch AW: Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells. Cancer Res 1978, 38:1730-1733.
• [9]Clark WM: Efficacy of citicoline as an acute stroke treatment. Expert Opin Pharmacother 2009, 10:839-846.
• [10]Bustamante A, Giralt D, Garcia-Bonilla L, et al.: Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J Neurochem 2012, 123:217-225.
• [11]Löwenberg B, Pabst T, Vellenga E, et al.: Cytarabine dose for acute myeloid leukemia. N Engl J Med 2011, 364:1027-1036.
• [12]Löwenberg B: Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 2013, 121:26-27.
• [13]Plunkett W, Liliemark JO, Adams TM, et al.: Saturation of 1-beta-D- arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 1987, 47:3005-3011.
• [14]Capizzi RL, Yang JL, Cheng E, et al.: Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia. J Clin Oncol 1983, 1:763-771.
• [15]Raza A, Preisler HD, Day R, et al.: Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood 1990, 76:2191-2197.
• [16]Leclerc JM, Momparler RL: Importance of the interval between exposures to cytosine arabinoside on its cytotoxic action on HL-60 myeloid leukemic cells. Cancer Treatment Rep 1984, 68:1143-1148.
• [17]Momparler RL, Onetto-Pothier N: Drug resistance to cytosine arabinoside. In Resistance to Antineoplastic Drugs. Edited by Kessel D. Boca Raton: CRC Press; 1988:353-367.
• [18]Flasshove M, Strumberg D, Ayscue L, et al.: Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia 1994, 8:780-785.
• [19]Onetto N, Momparler RL, Momparler LF, et al.: In vitro tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-aza-deoxycytidine. Semin Oncol 1987, 14:231-237.
• [20]Raynal NJ, Momparler LF, Rivard GE, et al.: 3-Deazauridine enhances the antileukemic action of 5-aza-2’-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. Leuk Res 2011, 35:110-118.
• [21]Momparler RL, Momparler LF: Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2’-deoxycytidine and 3-deazauridine. Cancer Chemother Phamacol 1989, 25:51-54.
• [22]Momparler RL, Bouffard DY, Momparler LF, et al.: Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine. Int J Cancer 1991, 49:573-576.
• [23]Momparler RL, Chu MY, Fischer GA: Studies on a new mechanism of resistance of L5178Y murine leukemic cells to cytosine arabinoside. Biochem Biophys Acta 1968, 161:481-493.
• [24]Eliolopoulos N, Momparler RL: Drug resistance to 5’-aza-2’-deoxycytidine, 2,2’- difluorodeoxycytidine and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998, 42:373-378.
• [25]Lachmann N, Brennig S, Phaltane R, et al.: Myeloprotection by cytidine deaminase gene transfer in antileukemic therapy. Neoplasia 2013, 15:239-248.
• [26]Kreis W, Chan K, Budman DR, et al.: Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res 1988, 48:1337-1342.
• [27]Ebrahem Q, Mahfouz RZ, Ng KP, et al.: High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 2012, 3:1137-1145.
• [28]Ho DH: Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973, 33:2816-2820.
• [29]Giacinti C, Giordano A: RB and cell cycle progression. Oncogene 2006, 25:5220-5227.
• [30]Momparler RL, Côté S, Momparler LF: Epigenetic action of decitabine (5-aza-2’- deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leuk Res 2013, 37:980-984.
• [31]Momparler RL, Momparler LF, Samson J: Comparison of the antileukemic activity of 5- aza-2’-deoxycytidine, 1-ß-D-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia. Leuk Res 1984, 8:1043-1049.
• [32]Momparler RL, Samson J, Momparler LF, et al.: Cell cycle effects and cellular pharmacology of 5-aza-2’-deoxycytidine. Cancer Chemother Pharmacol 1984, 13:191-194.
• [33]Sarry JE, Murphy K, Perry R, et al.: Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest 2011, 121:384-395.
• [34]van Rhenen A, Feller N, Kelder A, et al.: High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005, 11:6520-6527.
• [35]Morisot S, Wayne AS, Bohana-Kashtan O, et al.: High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia 2010, 24:1859-1866.
• [36]Scandura JM, Roboz GJ, Moh M, et al.: Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011, 118:1472-1480.
• [37]Thépot S, Lainey E, Cluzeau T, et al.: Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011, 10:2323-2330.
• [38]Soncini M, Santoro F, Gutierrez A, et al.: The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia. Biochim Biophys Acta 1832, 2013:114-120.
• [39]Wattel E, Preudhomme C, Hecquet B, et al.: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84:3148-3157.
• [40]Ng KP, Ebrahem Q, Negrotto S, et al.: p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia 2011, 25:1739-1750.
• [41]Mahfouz RZ, Englehaupt R, Juersivich JA, et al.: Non-Cytotoxic Differentiation TherapyBased On Mechanism of Disease Produces Complete Remission in MyelodysplasticSyndromes (MDS) with High Risk Cytogenetics. Abstract No. 1696; 54th ASH Annual Meeting 2012. https://ash.confex.com/ash/2012/webprogram/Paper51351.html webcite
• [42]Saunthararajah Y, Triozzi P, Rini B, et al.: p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol 2012, 39:97-108.
• [43]Raynal NJ, Charbonneau M, Momparler LF, et al.: Synergistic effect of 5-aza-2’- deoxycytidine and genistein in combination against leukemia. Oncol Res 2008, 17:223-230.